SHANGHAI MODERN PHARMACEUTICAL CO.,LTD.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 1996-11-27
- Employees
- 559
- Market Cap
- -
- Website
- http://www.shyndec.com
- Introduction
The company was founded in 1996 and is a high-tech enterprise in the pharmaceutical industry specializing in R&D, production and sales of pharmaceutical products, founded by academicians of the Chinese Academy of Engineering. The company was listed on the Shanghai Stock Exchange on June 16, 2004. Joined China Pharmaceutical Group Co., Ltd. in April 2010. The company is a pharmaceutical manufacturing enterprise whose main business is R&D, production and sales of pharmaceutical products. The products cover systemic anti-infective, cardiovascular, anti-tumor and immunomodulators, central nervous system, hormones, genitourinary system, digestive tract and metabolism, respiratory system, etc. The dosage forms include tablets, capsules, powder injections, small-volume injections, granules, suspensions, suppositories and ointments. Corporate honors include a five-star founded enterprise with integrity, the 2017 China Innovation Power Pharmaceutical Enterprise Certificate, and the 2017 China Innovation Power Pharmaceutical Enterprise Medal.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
81
Drug Approvals
Milnacipran Hydrochloride Tablets
- Product Name
- 盐酸米那普仑片
- Approval Number
- 国药准字H20247158
- Approval Date
- Jul 10, 2024
Benzocaine Buccal Tablets
- Product Name
- 苯佐卡因含片
- Approval Number
- 国药准字H20080386
- Approval Date
- Aug 29, 2023
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
- Product Name
- 奥美沙坦酯氢氯噻嗪片
- Approval Number
- 国药准字H20233539
- Approval Date
- May 12, 2023
Fosinopril Sodium Capsules
- Product Name
- 福辛普利钠胶囊
- Approval Number
- 国药准字H20080311
- Approval Date
- Mar 8, 2023
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT02357615
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai, China
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT02031861
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai, Shanghai, China